Latest Advances in mHSPC to Fight Tumor Heterogeneity: Experience from Australia and Japan

In this presentation, we will delve into the latest advancements in medical therapy for metastatic hormone-sensitive prostate cancer (mHSPC). Our discussion will encompass insights gained from randomized controlled trials (RCTs) and real-world evidence (RWE), highlighting experiences from both Australia, Japan and Taiwan. The session will also explore the transition from RCTs to RWE, discussing how real-world data can complement clinical trial findings and provide a more comprehensive understanding of treatment efficacy and safety. By examining the experiences of both Australian and Japanese experts, we aim to provide a holistic view of the current landscape of mHSPC drug therapy and offer practical insights for clinicians worldwide.

Join us as we navigate the evolving field of mHSPC treatment, bridging the gap between clinical research and real-world practice to enhance patient care and outcomes.